Experts at UT MD Anderson have numerous presentations throughout the ESMO Congress 2026 program. Note: Times are listed in either CEST (Central European Summer Time) or CET (Central European Time) as noted for each day.
Experts at UT MD Anderson have numerous presentations throughout the ESMO Congress 2026 program. Note: Times are listed in either CEST (Central European Summer Time) or CET (Central European Time) as noted for each day.
Friday, October 23 (All times are listed in CEST)
Transforming oncology with generative AI and autonomous tools
Educational session
13:30–15:00 (1:30–3 p.m.) │Cordoba Auditorium — Hall 4
Validating AI for oncology: Navigating the road to clinical implementation
14:30–14:45 (2:30–2:45 p.m.)
Presenter: Caroline Chung, M.D.
YO Mentorship session
Young oncologist session
13:30–14:30 (1:30–2:30 p.m.) │Toledo Auditorium — NCC
Early-phase clinical trials
Presenter: Timothy Yap, M.B.B.S., Ph.D.
Rapid oral: Breast cancer, early stage
Rapid oral session
16:15–17:45 (4:15–5:45 p.m.) │Barcelona Auditorium — Hall 9
Abstract 540RO: Ultrasensitive monitoring of early ctDNA dynamics during neoadjuvant treatment in early-stage triple-negative breast cancer: Pre-interim results from the B-STRONGER-I study
Presenter: Carlos Barcenas, M.D.
Emerging therapeutic strategies in advanced prostate cancer
Special symposium
16:15–17:45 (4:15–5:45 p.m.) │Burgos Auditorium — Hall 3
Chair: Ana Aparicio, M.D.
New targets (ADCs, new biologies)
17:15–17:35 (5:15–5:35 p.m.)
Presenter: Ana Aparicio, M.D.
Saturday, October 24 (All times are listed in CEST)
Rapid oral 2: Gynecological cancers
Rapid oral session
08:30–10:00 (8:30–10 a.m.) │Murcia Auditorium — Hall 3
Abstract 1245RO: Updated results from FONTANA: Torvutatug samrotecan (torvu-sam), a folate receptor α (FRα)-targeted antibody-drug conjugate (ADC), in patients (pts) with platinum-resistant ovarian cancer (PROC)
Presenter: Funda Meric-Bernstam, M.D.
Cellular therapy in solid tumors
Educational session
08:30–10:00 (8:30–10 a.m.) │Madrid Auditorium — Hall 4
Logistics of cellular therapy
09:10–09:30 (9:10–9:30 a.m.)
Presenter: Ecaterina Dumbrava, M.D.
Updates on myeloid neoplasms with a focus on medical oncology practice
Educational session
16:30–18:00 (4:30–6 p.m.) │Malaga Auditorium — Hall 3
Current treatment landscape of AML based on a comprehensive genomic assessment
16:30–16:50 (4:30–4:50 p.m.)
Presenter: Courtney DiNardo, M.D.
Sunday, October 25 (All times are listed in CET)
Rapid oral 1: Basic science and translational research
Rapid oral session
8:30–10:00 (8:30–10 a.m.) │ Leon Auditorium — Hall 4
Abstract 4244RO: NeoCOAST-2: Association of ctDNA clearance with clinical outcomes in a global platform Phase 2 perioperative trial
Presenter: Tina Cascone, M.D., Ph.D.
Rapid oral: Developmental therapeutic
Rapid oral session
8:30–10:00 (8:30–10 a.m.) │Cordoba Auditorium — Hall 4
Abstract 1006RO: Phase 1 study of FMC-376, a KRAS G12C equipotent ON+OFF inhibitor in pts with advanced KRAS G12C mutant solid tumors
Presenter: Marcelo Negrao, M.D.
More cures in early melanoma
Multidisciplinary session
14:45–16:00 (2:45–4 p.m.) │Leon Auditorium — Hall 4
Pathological response for the win
15:30–15:50 (3:30–3:50 p.m.)
Presenter: Victor Prieto, M.D., Ph.D.
Prevention, early detection and intervention
Proffered paper session
14:45–16:25 (2:45–4:25 p.m.) │Seville Auditorium — NCC
Abstract 3438O: Safety and immunogenicity of re-vaccination with Nous-209: A neoantigen vaccine for cancer interception in Lynch syndrome carriers
Presenter: Eduardo Vilar-Sanchez, M.D., Ph.D.
Monday, October 26 (All times are listed in CET)
New targets and strategies
Special symposium
08:30–10:00 (8:30–10 a.m.) │Leon Auditorium — Hall 4
Chair: Timothy Yap, M.B.B.S., Ph.D.
New small molecules
09:15–09:30 (9:15–9:30 a.m.)
Presenter: Timothy Yap, M.B.B.S., Ph.D.
From science to clinical use: Emerging systemic therapies for lung cancer
Educational session
10:15–11:45 (10:15–11:45 a.m.) │Almeria Auditorium — Hall 9
Biology and mechanisms of action of novel immunotherapies
10:35–10:55 (10:35–10:55 a.m.)
Presenter: Tina Cascone, M.D., Ph.D.
Emerging biological agents and their role in innate immunity modulation
Special symposium
14:45–16:15 (2:45–4:15 p.m.) │Leon Auditorium — Hall 4
Chair: Stéphane Champiat, M.D., Ph.D.
Bispecific antibodies
14:45–15:00 (2:45–3 p.m.)
Presenter: Stéphane Champiat, M.D., Ph.D.
Rapid oral: Prevention, early detection and intervention
Rapid oral session
14:45–16:15 (2:45–4:15 p.m.) │ Salamanca Auditorium — Hall 10
Abstract 1153RO: IGNITE-TX (Identifying Individuals for Genetic Testing & Treatment): A pilot randomized trial
Presenter: Núria Agustí, M.D.
IO-based systemic therapy in head and neck cancers
Special symposium
16:30–18:00 (4:30–6 p.m.) │Granada Auditorium — Hall 4
IO-based systemic therapy (including patient selection)
16:30–16:45 (4:30–4:45 p.m.)
Presenter: Renata Ferrarotto, M.D.
Posters (All are in the Poster Area in Hall 5)
Friday, October 23 (All times are listed in CEST)
15:15–16:00 (3:15–4 p.m.)
Developmental therapeutics
Abstract 1010P: Analysis of the safety, tolerability and PK of EIK1005, a novel WRN inhibitor
Presenter: Timothy Yap, M.B.B.S., Ph.D.
Abstract 1014P: ESPERANZA: Results from an external comparator study of trastuzumab deruxtecan in HER2 IHC3+ solid tumors
Presenter: Funda Meric-Bernstam, M.D.
Abstract 1018P: Phase 1 dose-escalation trial of novel TROP2-targeted antibody drug conjugate OBI-992 in patients with advanced solid tumors
Presenter: Apostolia Maria Tsimberido, MD., Ph.D.
Abstract 1025P: Phase 1a clinical trial of TTX-MC138, a first-in-class antagomir against advanced solid tumors
Presenter: Siqing Fu, M.D., Ph.D.
Abstract 1043P: First-in-human trial of BGB-58067, an MTA-cooperative PRMT5 inhibitor, in MTAP-deficient advanced tumors
Presenter: Jordi Rodon Ahnert, M.D., Ph.D.
Abstract 1057P: Tambotatug pelitecan (YL201): Analyses of interstitial lung disease in patients with advanced solid tumours from Phase 1/2 studies
Presenter: Siqing Fu, M.D., Ph.D.
Abstract 1072P: Safety and activity of IAM1363, a CNS penetrant HER2 TKI in participants with HER2-altered advanced cancers
Presenter: Ecaterina Dumbrava, M.D.
Abstract 1082TiP: Trial in Progress: Part 2 cohort expansion of a Phase 1 study of PLN-101095, a dual αvβ8/αvβ1 integrin inhibitor, in combination with pembrolizumab in immune checkpoint inhibitor-refractory advanced solid tumors
Presenter: Timothy Yap, M.B.B.S., Ph.D.
Translational research and biomarkers
Abstract 4403P: Clonal and subclonal resistance during anti-EGFR rechallenge in metastatic colorectal cancer
Presenter: Guglielmo Vetere, M.D.
Abstract 4440P: Goblet cell appendiceal adenocarcinoma is a distinct disease entity defined by LGR5/Wnt mediated oncogenesis driving an immune-excluded tumor microenvironment
Presenter: John Paul Shen, M.D.
Abstract 4445P: Prevalence, prognosis, and impact on tumor microenvironment (TME) of homozygous MTAP deletion (MTAP-del) in advanced solid tumors
Presenter: Jordi Rodon Ahnert, M.D., Ph.D.
Abstract 4260P: Clinical utility of reflex liquid comprehensive genomic profiling (LCGP) to complement tumor-informed circulating tumor DNA (ctDNA) monitoring in solid tumors
Presenter: Jason Mouabbi, M.D.
Abstract 4264P: Evaluation of ctDNA minimal residual disease (MRD) testing to complement radiographic surveillance in patients (Pts) with colorectal cancer (CRC): Results from the MD Anderson (MDA) INTERCEPT program
Presenter: Arvind Dasari, M.D.
Saturday, October 24 (All times are listed in CEST)
12:00–12:45 (12–12:45 p.m.)
Investigational immunotherapy
Abstract 1967P: COVID mRNA vaccines before immune checkpoint inhibitors: A target trial emulation and external validation cohort
Presenter: Sage Copling
1971P - Development of clinical benefit and progression-free survival scores for patient selection in early-phase immunotherapy trials
Presenter: Harold Nathan Tan, M.D.
Miscellaneous
Abstract 4863P: RNA‑seq phasing spotlights secondary oncogenic mutations for clinical interpretation
Presenter: Neeta Somaiah, M.D.
Non-melanoma skin tumors
Abstract 2490P: A Phase 2 study of neoadjuvant cemiplimab for stage II–IV cutaneous squamous cell carcinoma (CSCC): Final analysis
Presenter: Neil Gross, M.D.
Palliative care
Abstract 3105P: Impact of culture change duration prior to structural intervention on non-beneficial end-of-life (EOL) systemic anti-cancer therapy (SACT)
Presenter: Narmeen Somani
Sunday, October 25 (All times are listed in CET)
12:00–12:45 (12–12:45 p.m.)
AI for clinical research and drug development
Abstract 145P: Agentic large language model for auditable line-of-therapy extraction from unstructured electronic health records in colorectal cancer
Presenter: Cynthia Yeung, M.D.
Colon cancer
Abstract 797P: Overall survival in young- vs average-onset metastatic colorectal cancer across actionable molecular subgroups: A 4,717-patient hierarchical analysis at UT MD Anderson
Presenter: Cynthia Yeung, M.D.
Abstract 828P: Young-onset versus late-onset colorectal cancer in Phase 1 trials: Toxicity and survival outcomes
Presenter: Berta Martin-Cullell, M.D.
Abstract 860P: Organ-specific response to KRAS inhibitors in metastatic colorectal cancer
Presenter: Emerik Osterlund, M.D., Ph.D.
Abstract 863P: Chromosomal instability is associated with worse survival and an immunosuppressive tumor microenvironment in microsatellite stable colorectal cancer
Presenter: Paulino Tallón De Lara, M.D., Ph.D.
Esophagogastric cancer
Abstract 2953P: Immune checkpoint inhibitor efficacy in resectable microsatellite instability-high gastric or gastroesophageal junction cancer
Presenter: Ryan Morgan, M.D.
Pancreatic cancer
Abstract 3140P: Allele specific characteristics of KRASQ61-mutated gastrointestinal malignancies with clinical outcomes and transcriptomic features in pancreatic cancer
Presenter: Dan Zhao, M.D., Ph.D.
Abstract 3187TiP: A Phase 2 study evaluating navlimetostat (BMS-986504) and chemotherapy in resectable/borderline resectable (cohort 1), locally advanced, unresectable (cohort 2), and metastatic (cohort 3) MTAP-deleted pancreatic cancer
Presenter: Maria Pia Morelli, M.D., Ph.D.
Policy
Abstract 3380P: Stakeholder perspectives on cancer care capacity in Ukraine: Findings from a national needs assessment
Presenter: Darya Kizub, M.D.
Primary Prevention
Abstract 3456P: Survival associated with risk-reducing bilateral mastectomy versus screening in patients with pathogenic variants in BRCA1/2: A network meta-analysis
Presenter: Isabel Beshar, M.D.
Monday, October 26 (All times are listed in CET)
12:00–12:45 (12–12:45 p.m.)
Gynecological cancers
Abstract 1278P: LINNET: A Phase 2 study to evaluate lorigerlimab in participants (pts) with advanced gynecologic cancers
Presenter: Amir Jazaeri, M.D.
Abstract 1293P: Use of bevacizumab for the treatment of minimal residual disease (MRD) positive high-grade epithelial ovarian cancer: A Phase 2 study
Presenter: Amir Jazaeri, M.D.
Hematological malignancies
Abstract 1478P: Clinical prediction model for early mortality in leukemia patients following inpatient chemotherapy
Presenter: Musa Yilmaz, M.D.
Head and neck cancer, excluding thyroid
Abstract 1549P: A Phase 1a/1b trial of FAP-Dox (AVA6000), a fibroblast activation protein (FAP)-released and tumor microenvironment (TME)-targeted doxorubicin peptide drug conjugate in patients with salivary gland cancers
Presenter: Renata Ferrarotto, M.D.
Abstract 1578P: Neoadjuvant and adjuvant tiragolumab plus atezolizumab in PD-L1-positive oral cavity squamous cell carcinoma
Presenter: Luana Guimaraes de Sousa, M.D.
Non-small cell lung cancer, locally advanced
Abstract 2573P: Imneskibart (AU-007) + low-dose SC IL-2 + avelumab: Phase 2 activity in CPI refractory advanced adenocarcinoma NSCLC
Presenter: George Blumenschein, M.D.
Non-small cell lung cancer, metastatic
Abstract 2629P: Molecular dynamics and mechanisms of acquired resistance in NSCLC patients with EGFR PACC mutations treated with firmonertinib
Presenter: Xiuning Le, M.D., Ph.D.
Abstract 2652P: First-line (1L) Olomorasib + chemoimmunotherapy (Chemo-IO) in KRAS G12C-mutant NSCLC: Updated results from the LOXO-RAS-20001 and SUNRAY-01 trials
Presenter: Marcelo Negrao, M.D.
Abstract 2655P: Initial results from Phase 1/2 dose expansion cohorts: SAR445877 in immunotherapy-exposed advanced non-small cell lung cancer
Presenter: Aung Naing, M.D.
Abstract 2712P: SOHO-01: Updated efficacy and safety of sevabertinib in advanced HER2-mutant NSCLC, including first-line patients (pts) and those with active brain metastases
Presenter: Xiuning Le, M.D., Ph.D.
Sarcoma
Abstract 3760P: AXL protein expression by immunohistochemistry in sarcoma subtypes: Implications for antibody-drug conjugate development
Presenter: Carlos Torrado, M.D.
Give Now
Your gift will help make a tremendous difference.
Research Areas
Find out about the four types of research taking place at UT MD Anderson.
Subscribe
Get the latest information on our cancer breakthroughs.